Artiva Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
ARTV$4.22+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| YEAR ENDED DECEMBER 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(83,865) | $(65,373) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,597 | 2,431 |
| Stock-based compensation | 6,821 | 6,980 |
| Change in fair value of SAFEs (including related party amounts of $0 and $2,911, respectively) | — | 3,597 |
| Accretion of discounts and amortization of premiums on investments, net | (1,880) | (2,342) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable (including related party amounts of $0 and $569, respectively) | — | 1,034 |
| Other receivables (including related party amounts of $(61) and $607, respectively) | 79 | 578 |
| Prepaid expenses and other current assets | (1,534) | (1,965) |
| Other long-term assets | (191) | 125 |
| Accounts payable (including related party amounts of $(276) and $76, respectively) | (760) | 519 |
| Accrued expenses (including related party amounts of $(713) and $(1,447), respectively) | 2,003 | (659) |
| Operating lease right-of-use asset and lease liabilities, net | (21) | 43 |
| Net cash used in operating activities | (76,751) | (55,032) |
| Investing activities: | ||
| Purchases of property and equipment | (2,587) | (642) |
| Purchases of investments | (44,875) | (176,171) |
| Maturities of investments | 110,873 | 56,350 |
| Net cash provided by (used in) investing activities | 63,411 | (120,463) |
| Financing activities: | ||
| Proceeds from issuance of common stock, net of commissions | — | 166,507 |
| Proceeds from exercise of stock options | 138 | 51 |
| Proceeds from purchase of ESPP shares | 233 | — |
| Payments to taxing authorities related to net-settlement of vested restricted stock units | (230) | — |
| Payments on finance leases | (132) | (149) |
| Cash paid in connection with IPO offering costs | — | (4,183) |
| Net cash provided by financing activities | 9 | 162,226 |
| Net decrease in cash, cash equivalents and restricted cash | (13,331) | (13,269) |
| Cash, cash equivalents and restricted cash at beginning of period | 40,493 | 53,762 |
| Cash, cash equivalents and restricted cash at end of period | $27,162 | $40,493 |
| Reconciliation of cash, cash equivalents and restricted cash to the balance sheet: | ||
| Cash and cash equivalents | $26,701 | $40,235 |
| Restricted cash | 461 | 258 |
| Total cash, cash equivalents and restricted cash | $27,162 | $40,493 |
| Supplemental disclosures of noncash activities: | ||
| Right-of-use asset obtained in exchange for new operating lease liability | $442 | $— |
| Reduction in operating lease liabilities and right-of-use-assets from remeasurement | $546 | $— |
| Property and equipment purchases in accounts payable and accrued liabilities | $292 | $57 |
| Conversion of SAFE notes to common stock | $— | $28,697 |
| Conversion of preferred stock to common stock | $— | $216,413 |
| Non-cash additions to financing leases | $— | $241 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.